{"filing": {"accession": "0001493152-26-023740", "cik": "0001763950", "ticker": "LTRN", "company_name": "Lantern Pharma Inc.", "form_type": "10-Q", "filing_type": "10-Q", "filing_date": "2026-05-15", "accepted_datetime": null, "acceptance_datetime": null, "accepted_at": null, "primary_doc_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226023740/0001493152-26-023740-index.htm", "filing_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226023740/0001493152-26-023740-index.htm", "period_of_report": "2026-03-31"}, "html_url": "/api/filings/000149315226023740/stream", "exhibits": [], "sections": [{"section_name": "part_1", "section_title": "Part I", "start_position": 2691, "end_position": 3632}, {"section_name": "part_2", "section_title": "Part II", "start_position": 3632, "end_position": 3666}, {"section_name": "item_1a", "section_title": "Risk Factors", "start_position": 3666, "end_position": 96835}], "tables": [{"table_index": 0, "table_type": "text", "caption": null, "header_text": "Delaware001-3931846-3973463"}, {"table_index": 1, "table_type": "text", "caption": null, "header_text": "1920\n McKinney Avenue,7th FloorDallas,Texas75201"}, {"table_index": 2, "table_type": "text", "caption": null, "header_text": "Title\n of each classTrading\n SymbolName\n of each exchange on which registered"}, {"table_index": 3, "table_type": "text", "caption": null, "header_text": "Large\n accelerated filer\u2610Accelerated\n filer\u2610"}, {"table_index": 6, "table_type": "financial", "caption": null, "header_text": "Page"}, {"table_index": 9, "table_type": "financial", "caption": null, "header_text": "\u25cfthe\n existence of substantial doubt regarding our ability to continue as a going concern in the absence of obtaining substantial additional\n funding;"}, {"table_index": 12, "table_type": "text", "caption": null, "header_text": "\u25cfour\n ability to source our needs for skilled labor in the fields of artificial intelligence, genomics, biology, oncology and drug development;\n and"}, {"table_index": 15, "table_type": "financial", "caption": null, "header_text": "March 31, 2026December 31, 2025"}, {"table_index": 17, "table_type": "financial", "caption": null, "header_text": "20262025"}, {"table_index": 19, "table_type": "text", "caption": null, "header_text": "20262025"}, {"table_index": 21, "table_type": "financial", "caption": null, "header_text": "of SharesAmountSharesAmountCapitalIncome (Loss)DeficitEquity"}, {"table_index": 23, "table_type": "financial", "caption": null, "header_text": "20262025"}, {"table_index": 25, "table_type": "text", "caption": null, "header_text": "\u25cfLP-300\n (Tavocept), which we are advancing in a Phase 2 clinical trial, the Harmonic\u2122 trial, focused on never smokers with advanced\n non-small cell lung cancer;"}, {"table_index": 31, "table_type": "financial", "caption": null, "header_text": "20262025"}, {"table_index": 33, "table_type": "financial", "caption": null, "header_text": "March 31,December 31,"}, {"table_index": 35, "table_type": "financial", "caption": null, "header_text": "March 31,December 31,"}, {"table_index": 36, "table_type": "financial", "caption": null, "header_text": ""}, {"table_index": 37, "table_type": "financial", "caption": null, "header_text": "OperatingOperating"}, {"table_index": 39, "table_type": "text", "caption": null, "header_text": "20262025"}, {"table_index": 40, "table_type": "financial", "caption": null, "header_text": "20262025"}, {"table_index": 42, "table_type": "text", "caption": null, "header_text": "Options Outstanding"}, {"table_index": 43, "table_type": "text", "caption": null, "header_text": "20262025"}, {"table_index": 45, "table_type": "financial", "caption": null, "header_text": ""}, {"table_index": 46, "table_type": "text", "caption": null, "header_text": "20262025"}, {"table_index": 47, "table_type": "text", "caption": null, "header_text": "March 31, 2026December 31, 2025"}, {"table_index": 48, "table_type": "text", "caption": null, "header_text": "Three Months Ended March 31,2026Three Months Ended March 31,2025"}, {"table_index": 52, "table_type": "financial", "caption": null, "header_text": "\u25cfexpenses\n incurred towards research and development employees, consultants, outside contractors, laboratories, clinical sites, and investigators\n that conduct our preclinical or clinical research act"}, {"table_index": 53, "table_type": "financial", "caption": null, "header_text": "Three MonthsThree Months"}, {"table_index": 56, "table_type": "financial", "caption": null, "header_text": "Three Months Ended"}, {"table_index": 58, "table_type": "financial", "caption": null, "header_text": "For the Three MonthsEnded March 31,"}, {"table_index": 60, "table_type": "financial", "caption": null, "header_text": "\u25cfcontinue\n the development, including preclinical studies and clinical trials, of our drug candidates;"}, {"table_index": 63, "table_type": "exhibit_index", "caption": null, "header_text": "ExhibitNo.Exhibit\n DescriptionMethod\n of Filing"}, {"table_index": 65, "table_type": "text", "caption": null, "header_text": "Lantern\n Pharma Inc.,"}], "exhibits_pending": true, "cdn_html": true, "response_time_ms": 26}